[1] |
Schadendorf D, van Akkooi A, Berking C, et al. Melanoma[J]. Lancet, 2018,392(10151):971⁃984. doi: 10.1016/S0140⁃6736(18)31559⁃9.
|
[2] |
Liu Y, Young K, Rakotondraibe LH, et al. Antiproliferative compounds from cleistanthus boivinianus from the madagascar dry forest[J]. J Nat Prod, 2015,78(7):1543⁃1547. doi: 10.1021/np501020m.
|
[3] |
Oettgen HF, Aoki T, Old LJ, et al. Suspension culture of a pigment⁃producing cell line derived from a human malignant melanoma[J]. J Natl Cancer Inst, 1968,41(4):827⁃843.
|
[4] |
Luyten GP, Mooy CM, Post J, et al. Metastatic uveal melanoma. A morphologic and immunohistochemical analysis[J]. Cancer, 1996,78(9):1967⁃1971. doi: 10.1002/(sici)1097⁃0142(19961101)78:9<1967::aid⁃cncr18>3.0.co;2⁃w.
|
[5] |
Nareyeck G, Wuestemeyer H, von der Haar D, et al. Establishment of two cell lines derived from conjunctival melanomas[J]. Exp Eye Res, 2005,81(3):361⁃362. doi: 10.1016/ j.exer.2005.04.018.
|
[6] |
Nareyeck G, Zeschnigk M, Prescher G, et al. Establishment and characterization of two uveal melanoma cell lines derived from tumors with loss of one chromosome 3[J]. Exp Eye Res, 2006,83(4):858⁃864. doi: 10.1016/j.exer.2006.04.004.
|
[7] |
Zhang N, Wang L, Zhu GN, et al. The association between trauma and melanoma in the Chinese population: a retrospective study[J]. J Eur Acad Dermatol Venereol, 2014,28(5):597⁃603. doi: 10.1111/jdv.12141.
|
[8] |
Turajlic S, Furney SJ, Lambros MB, et al. Whole genome sequencing of matched primary and metastatic acral melanomas[J]. Genome Res, 2012,22(2):196⁃207. doi: 10.1101/gr.125591. 111.
|
[9] |
Kong Y, Si L, Zhu Y, et al. Large⁃scale analysis of KIT aberrations in Chinese patients with melanoma[J]. Clin Cancer Res, 2011,17(7):1684⁃1691. doi: 10.1158/1078⁃0432.CCR⁃10⁃2346.
|
[10] |
Si L, Kong Y, Xu X, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432⁃case cohort[J]. Eur J Cancer, 2012,48(1):94⁃100. doi: 10.1016/j.ejca.2011.06.056.
|
[11] |
Si L, Zhang X, Shu Y, et al. A phase Ib study of pembrolizumab as second⁃line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE⁃151)[J]. Transl Oncol, 2019,12(6):828⁃835. doi: 10.1016/j.tranon.2019.02.007.
|
[12] |
Chang KW, Lin SC, Chao SY, et al. Establishment and characterization of an oral melanoma cell line (ME)[J]. Oral Oncol, 2001,37(3):301⁃307. doi: 10.1016/s1368⁃8375(00)00116⁃0.
|
[13] |
Kaur J, Ralhan R. Establishment and characterization of a cell line from smokeless tobacco associated oral squamous cell carcinoma[J]. Oral Oncol, 2003,39(8):806⁃820. doi: 10.1016/s1368⁃8375(03)00084⁃8.
|
[14] |
Haugh AM, Johnson DB. Management of V600E and V600K BRAF⁃mutant melanoma[J]. Curr Treat Options Oncol, 2019,20(11):81. doi: 10.1007/s11864⁃019⁃0680⁃z.
|
[15] |
Bai X, Kong Y, Chi Z, et al. MAPK pathway and TERT promoter gene mutation pattern and its prognostic value in melanoma patients: a retrospective study of 2,793 cases[J]. Clin Cancer Res, 2017,23(20):6120⁃6127. doi: 10.1158/1078⁃0432.CCR⁃17⁃0980.
|